Behavior in early adolescence and risk of human papillomavirus infection as a young adult: Results from a population-based study

Pediatrics

Volumn 122, Issue 1, 2008, Pages 1-7

  Dempsey, Amanda F ^a   Gebremariam, Achamyeleh ^a   Koutsky, Laura ^b   Manhart, Lisa ^b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

, adolescent; Human papillomavirus; Risk factors; Vaccine

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENCE; ADOLESCENT; ARTICLE; DISEASE ASSOCIATION; FEMALE; HIGH RISK BEHAVIOR; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; INFECTION RISK; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEXUAL BEHAVIOR; UNITED STATES; VACCINATION; VERRUCA VULGARIS; VIRUS DETECTION; WART VIRUS; ADULT; DRINKING BEHAVIOR; LONGITUDINAL STUDY; RISK ASSESSMENT; RISK FACTOR; STATISTICAL MODEL; VIRUS INFECTION;

ADOLESCENT; ADULT; ALCOHOL DRINKING; FEMALE; HUMANS; LOGISTIC MODELS; LONGITUDINAL STUDIES; PAPILLOMAVIRUS INFECTIONS; RISK ASSESSMENT; RISK FACTORS; SEXUAL BEHAVIOR;

EID: 48249134029     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2007-2515     Document Type: Article

References (39)

1. US Food and Drug Administration. Product approval information: licensing action, Gardasil. Available at: www.fda.gov/cber/products/hpvmer060806qa.htm. Accessed August 1, 2006
2. Koutsky LA, Ault KA, Wheeler CM, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med. 2002; 347(21):1645-1651
3. Koutsky LA, Holmes KK, Critchlow CW, et al. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. N Engl J Med. 1992;327(18):1272-1278
4. villa LL, Costa RL, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 2005;6(5):271-278
5. villa LL, Costa RL, Petta CA, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/ 16/18 L1 virus-like particle vaccine through 5 years of follow- up. Br J Cancer. 2006;95(11):1459-1466
6. Bosch FX, de Sanjosé S. Human papillomavirus and cervical cancer: burden and assessment of causality. J Natl Cancer Inst Monogr. 2003;(31):3-13
7. Brown DR, Schroeder JM, Bryan JT, Stoler MH, Fife KH. Detection of multiple human papillomavirus types in Condylo- mata acuminata lesions from otherwise healthy and immuno- suppressed patients. J Clin Microbiol. 1999;37(10):3316-3322
8. Greer CE, Wheeler CM, Ladner MB, et al. Human papilloma- virus (HPv) type distribution and serological response to HPv type 6 virus-like particles in patients with genital warts. J Clin Microbiol. 1995;33(8):2058-2063
9. Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER. Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2007;56(RR-2):1-24
10. Centers for Disease Control and Prevention. vFC vaccine price list. Available at: www.cdc.govhttp://www.cdc.gov/vaccines/programs/vfc/cdc-vac- vaccines/programs/vfc/cdc-vac- price-list.htm. Accessed August 22, 2007
11. Gold RB. Challenges and opportunities for US family planning clinics in providing the HPv vaccine. Guttmacher Policy Rev. 2007;10(3):8-14
12. Lee GM, Santoli JM, Hannan C, et al. Gaps in vaccine financing for underinsured children in the United States. JAMA. 2007;298(6):638-643
13. Burk RD, Ho GY, Beardsley L, Lempa M, Peters M, Bierman R. Sexual behavior and partner characteristics are the predominant risk factors for genital human papillomavirus infection in young women. J Infect Dis. 1996;174(4):679-689
14. Manhart LE, Holmes KK, Koutsky LA, et al. Human papillo- mavirus infection among sexually active young women in the United States: implications for developing a vaccination strategy. Sex Transm Dis. 2006;33(8):502-508
15. Tarkowski TA, Koumans EH, Sawyer M, et al. Epidemiology of human papillomavirus infection and abnormal cytologic test results in an urban adolescent population. J Infect Dis. 2004; 189(1):46-50
16. Wheeler CM, Parmenter CA, Hunt WC, et al. Determinants of genital human papillomavirus infection among cytologically normal women attending the University of New Mexico student health center. Sex Transm Dis. 1993;20(5):286-289
17. Udry JR. The National Longitudinal Study ofAdolescent Health (Add Health), Waves I and II, 1994-1996. Chapel Hill, NC: Carolina Population Center, University of North Carolina at Chapel Hill; 1998
18. Resnick MD, Bearman PS, Blum RW, et al. Protecting adolescents from harm: findings from the National Longitudinal Study on Adolescent Health. JAMA. 1997;278(10):823-832
19. Add Health Biomarkers Team. Biomarkers in Wave III of the Add Health Study. Chapel Hill, NC: University of North Carolina at Chapel Hill; 2005. Available at: www.cpc.unc.edu/projects/addhealth/files/biomark.pdf. Accessed July 1, 2007
20. Ford CA, Pence BW, Miller WC, et al. Predicting adolescents' longitudinal risk for sexually transmitted infection: results from the National Longitudinal Study of Adolescent Health. Arch Pediatr Adolesc Med. 2005;159(7):657-664
21. Fortenberry JD. Adolescent substance use and sexually transmitted diseases risk: a review. J Adolesc Health. 1995;16(4): 304-308
22. White HR, Johnson v. Risk taking as a predictor of adolescent sexual activity and use of contraception. J Adolesc Res. 1988;3(3-4):317-331
23. Ford K, Lepkowski JM. Characteristics of sexual partners and STD infection among American adolescents. Int J STD AIDS. 2004;15(4):260-265
24. Bachanas PJ, Morris MK, Lewis-Gess JK, et al. Psychological adjustment, substance use, HIv knowledge, and risky sexual behavior in at-risk minority females: developmental differences during adolescence. J Pediatr Psychol. 2002;27(4):373-384
25. Brown DR, Shew ML, Qadadri B, et al. A longitudinal study of genital human papillomavirus infection in a cohort of closely followed adolescent women. J Infect Dis. 2005;191(2):182-192
26. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med. 1998;338(7):423-428
27. Moscicki AB, Schiffman M, Kjaer S, villa LL. Updating the natural history of HPv and anogenital cancer. vaccine. 2006;24(suppl 3):S42-S51
28. Woodman CB, Collins S, Winter H, et al. Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Lancet. 2001;357(9271):1831-1836
29. Alter MJ, Hadler SC, Margolis HS, et al. The changing epidemiology of hepatitis B in the United States: need for alternative vaccination strategies. JAMA. 1990;263(9):1218-1222
30. Centers for Disease Control and Prevention. Update: recommendations to prevent hepatitis B virus transmission: United States. MMWR Morb Mortal Wkly Rep. 1995;44(30):574-575
31. Advisory Committee on Immunization Practices, American Academy of Pediatrics, American Academy of Family Physicians, American Medical Association. Immunization of adolescents: recommendations of the Advisory Committee on Immunization Practices, the American Academy of Pediatrics, the American Academy of Family Physicians, and the American Medical Association. MMWR Recomm Rep. 1996;45(RR-13):1-16
32. Fiore AE, Wasley A, Bell BP. Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2006;55(RR-7):1-23
33. Centers for Disease Control and Prevention. Genital HPv infection. Available at: www.cdc.gov/std/HPv/STDFact-HPv. htm. Accessed August 4, 2007
34. Winer RL, Feng Q, Hughes JP, et al. Risk of female human papillomavirus acquisition associated with first male sex partner. J Infect Dis. 2008;197(2):279-282
35. Winer RL, Lee SK, Hughes JP, Adam DE, Kiviat NB, Koutsky LA. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol. 2003;157(3):218-226
36. Forslund O, Hansson BG, Rymark P, Bjerre B. Human papil- lomavirus DNA in urine samples compared with that in simultaneously collected urethra and cervix samples. J Clin Microbiol. 1993;31(8):1975-1979
37. Strauss S, Jordens JZ, McBride D, et al. Detection and typing of human papillomavirus DNA in paired urine and cervical scrapes. Eur J Epidemiol. 1999;15(6):537-543
38. Jacobson DL, Womack SD, Peralta L, et al. Concordance of human papillomavirus in the cervix and urine among inner city adolescents. Pediatr Infect Dis J. 2000;19(8):722-728
39. GlaxoSmithKline. GlaxoSmithKline initiates head-to-head study of cervical cancer vaccines. Available at: www.gsk.com/ControllerServlet?appId = 4&pageId=402&newsid = 959. Accessed August 15th, 2007